Navigation Links
New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism
Date:2/20/2013

ction to PRADAXA (e.g., anaphylactic reaction or anaphylactic shock)
  • A mechanical prosthetic heart valve 
  • WARNINGS & PRECAUTIONS 
    Risk of Bleeding

    PRADAXA increases the risk of bleeding and can cause significant and, sometimes, fatal bleeding. Promptly evaluate any signs or symptoms of blood loss (e.g., a drop in hemoglobin and/or hematocrit or hypotension). Discontinue PRADAXA in patients with active pathological bleeding.

    Risk factors for bleeding include concomitant use of medications that increase the risk of bleeding (e.g., anti-platelet agents, heparin, fibrinolytic therapy, and chronic use of NSAIDs). PRADAXA's anticoagulant activity and half-life are increased in patients with renal impairment. 

    A specific reversal agent for dabigatran is not available. Hemodialysis can remove dabigatran; however clinical experience for hemodialysis as a treatment for bleeding is limited. Activated prothrombin complex concentrates, recombinant Factor VIIa, or concentrates of factors II, IX or X may be considered but their use has not been evaluated. Protamine sulfate and vitamin K are not expected to affect dabigatran anticoagulant activity. Consider administration of platelet concentrates where thrombocytopenia is present or long-acting antiplatelet drugs have been used. 

    Thromboembolic and Bleeding Events in Patients with Prosthetic Heart Valves
    The safety and efficacy of PRADAXA in patients with bileaflet mechanical prosthetic heart valves (recently implanted or implanted more than 3 months prior to enrollment) was evaluated in the phase 2 RE-ALIGN trial. RE-ALIGN was terminated early because of significantly more thromboembolic events (valve thrombosis, stroke, transient ischemic attack, and myocardial infarction) and an excess of major bleeding (predominantly post-operative pericardial effusions requiring intervention for hemodynamic compromise) for PRADAXA vs warfarin. Therefore, the use
    '/>"/>

    SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
    2. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
    3. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
    4. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
    5. Shingles Vaccine is Safe, According to New Study
    6. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
    7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
    8. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
    9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
    10. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
    11. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/1/2015)... 1, 2015 UT Southwestern Medical Center President ... members joined U.S. Representatives Michael C. Burgess , ... discussion on the 21 st Century Cures Act, ... considered by the United States ... Academy of Sciences members, department chairs, center directors, and ...
    (Date:9/1/2015)... Conn. , Sept. 1, 2015  Results from ... AD™ study demonstrate that 5g of idarucizumab enabled ... situations involving patients treated with dabigatran (Pradaxa ® ... of the anticoagulant effect of dabigatran enabled patients ... a median time of 1.7 hours between administration ...
    (Date:9/1/2015)... SAN DIEGO , Sept. 1, 2015 Agena ... in Shanghai , a commercial and financial ... the growing number of genomic testing laboratories in mainland ... a significant portion of Agena Bioscience,s global sales with almost ... within China will allow us to ...
    Breaking Medicine Technology:U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 4U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 2New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 3New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 4New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 6New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 7New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 8New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 9Agena Bioscience Opens Office in Shanghai, China 2
    ... EDAP TMS S.A. (Nasdaq:,EDAP), the global leader ... cancer, is currently conducting clinical,investigations in France under ... with chemotherapy using docetaxel. The study is ... from,clinically localized but aggressive high risk prostate cancer ...
    ... WKN,918864) , ,AURORA, ON, March ... BioPharma Corp., a developer of novel cancer therapeutics,will be ... Tumor Microenvironment, which runs from March 6th to,10th in ... hosted by the International Cancer Microenvironment,Society, is a premier ...
    Cached Medicine Technology:EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer 2EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer 3Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at,the Fourth International Conference on Tumor Microenvironment in,Florence, Italy 2Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at,the Fourth International Conference on Tumor Microenvironment in,Florence, Italy 3Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at,the Fourth International Conference on Tumor Microenvironment in,Florence, Italy 4
    (Date:9/1/2015)... San Jose, CA (PRWEB) , ... September 01, ... ... in cross-device computing and collaboration, announces Splashtop Business for Remote Support , ... best-in-class remote support solution. Unhappy with the escalating renewal prices and inadequate ...
    (Date:9/1/2015)... ... September 01, 2015 , ... Virginia entrepreneur Marcella Ellis, CEO ... maintaining her firm’s success in the hair care and distribution industry through her ... Ellis will be providing “Look and learn” live demonstrations, as well as promoting ...
    (Date:9/1/2015)... ... September 01, 2015 , ... ... top-five hospital by U.S. News & World Report, to provide breaking news and ... Editorial and marketing groups within OncLive, which provides oncologists resources and information?they need ...
    (Date:9/1/2015)... ... 2015 , ... The Jerry Segal Classic to benefit the patients of Magee ... Club in Lafayette Hill, PA. Over the past 26 years, the Classic, organized by ... services designed to support patients and their families during their time at Magee Rehabilitation ...
    (Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... With former ... Engineering and Math) disciplines since its inception more than 35 years ago. A pilot ... students and their teachers - and, not just those intent on pursuing careers in ...
    Breaking Medicine News(10 mins):Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 2Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 4Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 3Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2
    ... 2009: DNA vaccination using lupus autoantigens and interleukin-10 (IL-10, ... the immune system) has potential as a novel therapy ... prevent kidney damage in patients with systemic lupus erythematosus ... EULAR 2009, the Annual Congress of the European League ...
    ... experts say , THURSDAY, June 11 (HealthDay News) -- ... first influenza pandemic since 1968, triggered by the H1N1 ... Europe and regions beyond, agency officials said. , The ... flu outbreak from phase 5, where it has remained ...
    ... lecturer lends his expertise to special ed school ... Academy,s Board of Trustees voted unanimously during its May meeting ... the nonprofit, state approved school. , , Dr. ... as both its Chief Executive Officer and Chief Scientific Officer. ...
    ... SYK ) announced today that it will host a ... Time, to discuss the Company,s operating results for the quarter ended ... the quarter ended June 30, 2009 will be released at 4:00 ... call dial 866-700-0133 (domestic) or 617-213-8831 (international) ...
    ... 11 June 2009: Undertaking a supervised exercise programme ... physical function, reduce the need for daily corticosteroid ... and anxiety in people with rheumatoid arthritis (RA), ... EULAR 2009, the Annual Congress of the European ...
    ... industrial sites and petrochemical spillages often involves finding microbes ... leaves behind a non-toxic residue or mineralized material. Writing ... , researchers in China describe studies of a new ... Yan-Jun Chen College of Water Sciences, Beijing Normal University, ...
    Cached Medicine News:Health News:Novel DNA vaccine leads to kidney damage prevention in systemic lupus erythematosus models 2Health News:Swine Flu Now a Pandemic: WHO 2Health News:Swine Flu Now a Pandemic: WHO 3Health News:Swine Flu Now a Pandemic: WHO 4Health News:Swine Flu Now a Pandemic: WHO 5Health News:Swine Flu Now a Pandemic: WHO 6Health News:Swine Flu Now a Pandemic: WHO 7Health News:Swine Flu Now a Pandemic: WHO 8Health News:Swine Flu Now a Pandemic: WHO 9Health News:Swine Flu Now a Pandemic: WHO 10Health News:Swine Flu Now a Pandemic: WHO 11Health News:Swine Flu Now a Pandemic: WHO 12Health News:Dr. Philip A. DeFina of International Brain Research Foundation Joins Montgomery Academy Board of Trustees 2Health News:Stryker to Host Conference Call on July 21, 2009 2Health News:Exercise improves functional and psycological ability and reduces steroid need in rheumatoid arthritis 2Health News:The microbial hydrocarbon diet 2
    ... Kit Nebulizer Small Volume Medication Mouthpiece 7FT ... ,These Sidestream® nebulizers are designed ... for any nebulizer treatment with a fast treatment ... with 7` (84") tubing and a vent seal ...
    Nebulizer Adapter Kit 6"...
    ... in Anesthesia and Respiratory Products, ,Westmed ... devices for Anesthesia and Respiratory professionals. Our ... that enhance the clinician's ability to deliver ... to the bottom line. , ,Our ...
    ... Anesthesia and Respiratory Products, ,Westmed designs, ... for Anesthesia and Respiratory professionals. Our mission ... enhance the clinician's ability to deliver quality ... the bottom line. , ,Our web ...
    Medicine Products: